表紙
市場調査レポート

腎症:パイプライン製品の分析

Nephropathy - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 271836
出版日 ページ情報 英文 59 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
腎症:パイプライン製品の分析 Nephropathy - Pipeline Review, H1 2016
出版日: 2016年04月13日 ページ情報: 英文 59 Pages
概要

腎症は、腎臓の疾患であり、不眠、食欲不振、胃痛、衰弱などの症状が現れます。発症要因は病的な肥満、高血圧、高脂肪および高血糖、喫煙などです。投薬および食生活の改善で管理を行います。

当レポートでは、腎症に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースなどについて、体系的な情報を提供しています。

イントロダクション

  • 調査範囲

腎症の概要

治療薬の開発

  • パイプライン製品の概要

腎症:企業で開発中の治療薬

腎症:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

腎症:企業で開発中の製品

腎症の治療薬開発に従事している企業

  • Baxalta Incorporated
  • ChemoCentryx, Inc.
  • Complexa, Inc.
  • Omeros Corporation
  • Promedior, Inc.

腎症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

腎症:最近のパイプライン動向

腎症:休止中のプロジェクト

腎症:開発が中止された製品

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7909IDB

Summary

Global Markets Direct's, 'Nephropathy - Pipeline Review, H1 2016', provides an overview of the Nephropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nephropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nephropathy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Nephropathy
  • The report reviews pipeline therapeutics for Nephropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Nephropathy therapeutics and enlists all their major and minor projects
  • The report assesses Nephropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Nephropathy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Nephropathy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nephropathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nephropathy Overview
  • Therapeutics Development
    • Pipeline Products for Nephropathy - Overview
  • Nephropathy - Therapeutics under Development by Companies
  • Nephropathy - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Nephropathy - Products under Development by Companies
  • Nephropathy - Companies Involved in Therapeutics Development
    • Baxalta Incorporated
    • ChemoCentryx, Inc.
    • Complexa, Inc.
    • Omeros Corporation
    • Promedior, Inc.
  • Nephropathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CCX-168 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CXA-10 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • imatinib mesylate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMS-721 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PRM-151 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • R-190 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • R-801 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • R-901 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SM-101 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit Casein Kinase 2 for Cancer and Nephritis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Nephropathy - Recent Pipeline Updates
  • Nephropathy - Dormant Projects
  • Nephropathy - Discontinued Products
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Nephropathy, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Nephropathy - Pipeline by Baxalta Incorporated, H1 2016
  • Nephropathy - Pipeline by ChemoCentryx, Inc., H1 2016
  • Nephropathy - Pipeline by Complexa, Inc., H1 2016
  • Nephropathy - Pipeline by Omeros Corporation, H1 2016
  • Nephropathy - Pipeline by Promedior, Inc., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Nephropathy Therapeutics - Recent Pipeline Updates, H1 2016
  • Nephropathy - Dormant Projects, H1 2016
  • Nephropathy - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Nephropathy, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Targets, H1 2016
  • Number of Products by Stage and Targets, H1 2016
  • Number of Products by Mechanism of Actions, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top